Molecular vision in collaboration to produce diagnostic device
4 July 2007
Geneva. Molecular Vision Ltd, an offshoot from Imperial College, London, has
teamed up with Acrongenomics Inc., (OTCBB:AGNM) and design company Pearson
Matthews Ltd to develop a point-of-care medical diagnostic device for
detecting kidney and cardiac biomarkers.
The prototype device will use
proprietary Molecular Vision technology that uses organic light emitters and
photodetectors, coupled with microfluidics to detect characteristic
chemicals, called biomarkers, in bodily fluids.
The technology, which was first demonstrated in March 2007, uses the
optical characteristics of labelled biomarker molecules to identify them
using fluorescence, absorption, chemiluminesence or any of the other usual
optical detection methods.
Chris Wright, Executive Chairman of Molecular
Vision, said, “We are looking forward to working with Pearson Matthews and
Acrongenomics on the development of our first commercial product. In
combination, the three of us are able to provide innovative technology,
product design and access to the market place.”